Sun Pharmaceutical acquisition of Organon for $11.75B creates one of the world largest biosimilar platforms. For API suppliers, the deal opens new CDMO partnership opportunities across biosimilars and specialty generics.

The FDA's May 15 approval of IMMGOLIS and IMMGOLIS INTRI marks a pivotal expansion in the TNF-alpha inhibitor biosimilar market. For API and intermediate suppliers, this opens new demand channels.

Big pharma is offloading manufacturing facilities to CDMOs at an accelerating pace, with three major deals in March-April 2026. This wave reflects tariff-driven onshoring and a shift toward flexible outsourced manufacturing.

Gilead's Hepcludex has received FDA accelerated approval as the first-ever treatment for chronic hepatitis delta virus. As a peptide-based entry inhibitor, the approval creates significant demand for specialized peptide API manufacturing capacity.